Tailwinds' Take: it looks like Dr. Day is being given the keys to the house as the founder steps aside. The new CEO's background and resume are impeccable and it's great to see someone of his experience take over...
On Friday, my favorite little boom or bust biotech, Bioasis, reported their results. There is very little to learn from looking at the numbers; this is a tiny, pre-revenue company. However, in the MD&A section of the filing was...
Every year for the past 36 years, Byron Wien has put out a list of “Top 10 Surprises” for the coming year. The list is comprised of potential macroeconomic events that have, according to Mr. Wien,...
Tailwinds' Take: while this news comes suddenly and will likely cause some selling in the stock, we view it as constructive. Mark Day has never gotten the traction needed with financing and, frankly, our communications with him have been...
Tailwinds' Take: Bioasis appears to have done the necessary pre-clinical work to attract interest from partners. While still early stage, it's apparent that the platform has significant promise and I expect to see more deals in the near future. GUILFORD,...
Those who know me well are well aware that Wednesdays are my favorite night of the week. That's the night I go out mountain biking with The Gestalt Haus Gang, ending up at a similarly-named (mountain) biker bar tipping...
When I removed Bioasis from the Tailwinds Select Portfolio, it was with great reluctance. This is a Company that I believe has groundbreaking, lifesaving, technology. The management team is strong and the board is outstanding. All the pieces were...
Tailwinds' Take: Positive in that the timeline for development appears to be unchanged post the meeting, so that implies there were no significant issues from the FDA's side. How they fund this going forward remains a mystery to me....
GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc . (OTCQB:BIOAF; TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas...
Tailwinds' Take: the science behind XB3™ appears to be very interesting to the medical community. Hopefully this translates into some strategic partnerships soon. GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI), ), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform...
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.